Statement of Principles concerning polycythaemia vera (Balance of Probabilities) (No. 88 of 2021)

This instrument is a Statement of Principles made by the Repatriation Medical Authority under subsection 196B(3) of the Veterans' Entitlements Act 1986 (VEA) (see s3). It specifies the medical and factual factors that, on the balance of probabilities, must exist for polycythaemia vera or death from polycythaemia vera to be considered related to a person’s relevant service for the purposes of claims that fall under section 120B of the VEA or section 339 of the Military Rehabilitation and Compensation Act 2004 (MRCA) (see s5). The Statement commences on 20 September 2021 and formally replaces the prior Statement of Principles for polycythaemia vera No. 12 of 2013 (see s2 and s4).

Mechanically, the instrument (1) defines the disease, its scope and exclusions (s7(2), (3), (4)); (2) sets the evidentiary threshold and identifies specific factors that, if present and related to relevant service, allow a finding that the disease or death is service-related on the balance of probabilities (s8, s9); and (3) explains how a factor that refers to another disease covered by a different Statement of Principles is to be treated (s11). The Schedule 1 Dictionary supplies operative definitions used throughout, including the calculation of "one pack-year", the meaning of "relevant service", and what constitutes a "terminal event" for death claims.

The two discrete causal pathways the Statement accepts are: a smoking-related pathway requiring quantified tobacco exposure and timing (s9(1) together with the Schedule definitions), and a healthcare-access pathway based on "inability to obtain appropriate clinical management" (s9(2)). Section 10 requires that whatever factor is relied on must be related to the person’s relevant service, and places a particular limit on the clinical-management factor where the disease was suffered or contracted before or during, but did not arise out of, relevant service (s10(2)). The Statement also expressly includes death from a terminal event contributed to by polycythaemia vera (s7(5) and Schedule definition of "terminal event").

In short, the instrument is an evidentiary standard-setting device: it does not itself create entitlements or administrative procedures, but it prescribes the factual and medical conditions decision‑makers must treat as establishing causal connection to relevant service, subject to the provisions of the VEA and MRCA cited in s5.

The Statement codifies a limited set of medico‑factual concepts and the relationship those concepts must have to "relevant service" for the purposes of veteran and defence member compensation claims. Its central medical concept is the statutory definition of polycythaemia vera (s7(2)). That definition accepts a clinicopathological characterisation: a chronic Philadelphia‑chromosome negative myeloproliferative neoplasm with proliferation of bone marrow cells of all types producing elevated red cell measures and usually excess platelets and white blood cells. The instrument expressly includes masked or bled down polycythaemia vera and expressly excludes relative, familial and congenital polycythaemia and secondary polycythaemia from hypoxaemia or increased erythropoietin (s7(2)(b) and (c)). The Statement also notes the ICD‑10‑AM code D45 is the code for polycythaemia vera but instructs that the operative meaning for this instrument is the textual definition in s7(2) rather than the code alone (s7(3)‑(4)).

Causation is framed probabilistically. Section 8 records the Repatriation Medical Authority’s view, on the medical scientific evidence available, that it is more probable than not that polycythaemia vera and death from it can be related to relevant service. That is the justificatory standard for setting the factors in s9; the practical effect is that the factors in s9 are the circumstances that, if established and linked to relevant service, are sufficient to satisfy the balance of probabilities test for causal connection in relevant claims.

Section 9 sets out the only two factors that the Authority accepts as sufficient for the required causal connection: a quantified smoking exposure (s9(1)) and inability to obtain appropriate clinical management for polycythaemia vera (s9(2)). The smoking factor is precise: at least 10 pack‑years before clinical onset, smoking commencing at least five years before clinical onset, and if smoking ceased before onset, onset must have occurred within 15 years of cessation (s9(1)). The Schedule defines one pack‑year and explains how to calculate pack‑years (Schedule, definitions). The clinical‑management factor is framed as inability to obtain appropriate clinical management but the instrument does not define "appropriate clinical management", so its application will require interpretation in context (s9(2)).

Relationship to service is a discrete requirement: a factor under s9 must be related to relevant service (s10(1)). The clinical‑management factor is explicitly limited to material contribution to, or aggravation of, polycythaemia vera where the disease was suffered or contracted before or during but did not arise out of relevant service (s10(2)). Finally, the Statement makes provision for cross‑references: if a s9 factor relates to an injury or disease already the subject of a different Statement of Principles under s196B(3) of the VEA, the provisions of that other Statement apply as in force from time to time (s11).

The instrument operates within the statutory claims framework of the VEA and the MRCA. It applies to claims to which section 120B of the VEA or section 339 of the MRCA apply (s5). The Statement therefore affects persons who bring, or administer, claims under those provisions of the VEA and MRCA where polycythaemia vera or death from polycythaemia vera is asserted as service‑related. The Repatriation Medical Authority is the body that made the Statement; the Authority’s role is limited to determining the Statement under its delegated power in the VEA (s3). The Statement will be used by the decision‑makers under the VEA and MRCA when assessing causation in claims, because it sets the factors that are taken to establish a relationship to relevant service on the balance of probabilities (s8, s9).

"Relevant service" is defined in the Schedule and therefore narrows the pool of affected claimants to those whose service meets one of the listed categories: eligible war service (other than operational service) under the VEA; defence service (other than hazardous service and British nuclear test defence service) under the VEA; or peacetime service under the MRCA (Schedule, definitions). That definition affects the eligibility boundary for claims that may rely on this Statement. The Statement will also interact with existing Statements of Principles for other diseases: if a factor in s9 refers to another injury or disease that already has a Statement of Principles made under s196B(3) of the VEA, then the factors in that other Statement will apply (s11). This means practitioners who advise claimants must check for any relevant overlapping Statements when preparing or defending claims.

Practically, the instrument primarily affects three groups: (a) claimants seeking to establish that polycythaemia vera or death from it is connected to their service; (b) medical assessors and treating clinicians who provide the clinical history and timing evidence that will be used to meet the Statement’s factors (for example, records that establish "clinical onset"); and (c) administrative decision‑makers applying the VEA and MRCA who must assess whether the Statement’s requirements are met and related to relevant service (s8, s9, s10). The instrument does not itself create entitlement or provide remedies; it supplies the causal criteria used within the existing statutory decision framework.

The Statement does not create freestanding duties in the penal or administrative sense; instead it prescribes the factual criteria used to determine whether polycythaemia vera or death from polycythaemia vera can be regarded as related to relevant service on the balance of probabilities. The operative "duties" are therefore duties of proof and connection in the claims process under the VEA and MRCA rather than duties imposed directly by the Statement. Section 9 functions as the core rights‑establishing mechanism: if at least one of the factors in s9 exists and is related to relevant service under s10, it can be said on the balance of probabilities that the disease or death is connected with the circumstances of the person's relevant service (s9, s10).

Claimants effectively have the right to rely on the Statement as an authoritative list of factors that will establish causal connection if proved and related to service (s8, s9). Conversely, decision‑makers have the right to treat the presence of a s9 factor, when related to service, as sufficient for causation as a matter of application of the Statement. Section 11 preserves the operation of other Statements of Principles: if a s9 factor refers to an injury or disease covered by another Statement of Principles, the factors in that other Statement apply as in force from time to time (s11). That mechanism allocates rights and expectations across potentially overlapping medical conditions.

Specific procedural or evidentiary obligations are not set out in this instrument; rather, it contains substantive thresholds. The Schedule supplies definitional tools that constrain how those thresholds are to be evaluated. For example, the Schedule defines "one pack‑year" and gives a method for calculating pack‑years (Schedule, definitions). The Statement therefore creates the substantive requirement that smoking exposure be quantified using the pack‑year measure described. Similarly, the Statement defines "terminal event" and includes several examples (Schedule, definitions), which determines how "death from polycythaemia vera" is to be read for claim purposes (s7(5) and Schedule).

The instrument also limits the scope for the clinical‑management factor: s10(2) confines that factor to situations where the person’s polycythaemia vera was suffered or contracted before or during, but did not arise out of, relevant service, and where inability to obtain appropriate clinical management materially contributed to or aggravated the condition. That is a substantive constraint on the rights to rely on s9(2).

In short, the Statement establishes substantive thresholds that function as rights and burdens in the VEA/MRCA claims process: claimants must establish the factual elements in s9 and their nexus to relevant service under s10 for the Statement to operate in their favour; administrators and medical advisers must apply the Schedule definitions and s11 cross‑references when making causation findings.

The instrument itself contains no penal provisions, fines, or criminal sanctions. It is a Statement of Principles made under s196B(3) of the VEA (s3) and its function is to set the medical causal factors used in administrative determinations of service connection. The Statement does not prescribe administrative enforcement mechanisms; instead, it supplies substantive criteria for the adjudication of claims under the VEA and MRCA, which themselves provide the procedural and remedial framework (s5).

Enforcement, in the sense of implementation, falls within the decision‑making processes legislated in the VEA and the MRCA. This instrument will be used by those decision‑makers as part of their statutory role to assess claims covered by section 120B of the VEA or section 339 of the MRCA (s5). The Statement does not itself identify which agency or official is to make the ultimate entitlement determination; however, by virtue of being made under s196B(3) of the VEA (s3), it is intended to be an authoritative medical standard to be applied within those statutory schemes.

Because the Statement sets evidentiary thresholds, the practical "enforcement" is procedural: claimants must adduce and decision‑makers must evaluate evidence to establish the presence of the factors in s9 and their relationship to relevant service per s10. Where a factor relates to another disease that has its own Statement, s11 requires application of that other Statement's factors as in force. The instrument does not create an independent right of administrative review or judicial review; review rights and enforcement are those provided by the VEA and MRCA and by general administrative law doctrines, none of which are contained or amended in the text of this Statement.

Finally, the instrument repeals the earlier Statement No. 12 of 2013 (s4). The practical enforcement implication is that decisions taken after the commencement date (20 September 2021, s2) will be guided by the present Statement rather than the repealed 2013 Statement. Any procedural or remedial consequences from that change will arise through the ordinary claims and review mechanisms in the VEA and MRCA rather than from the Statement itself.

The Statement is made under a specific power in the VEA (subsection 196B(3)) and is expressly designed to operate within the claims frameworks provided in the VEA and MRCA. Section 5 states the instrument applies to claims to which section 120B of the VEA or section 339 of the MRCA apply. The practical legal interaction is therefore integrative: this Statement provides the medical cause factors that decision‑makers must consider when applying the substantive and procedural rules in those Acts. The Statement does not, and cannot, override procedural requirements, review mechanisms, or entitlement conditions that are set out in the VEA and MRCA themselves; rather, it supplies the medical causation criteria used within those frameworks.

Section 11 expressly addresses interactions with other Statements of Principles made under subsection 196B(3) of the VEA. If a factor in s9 refers to an injury or disease that is the subject of another Statement, then that other Statement’s factors "apply in accordance with the terms of that Statement of Principles as in force from time to time" (s11). This creates an orderly hierarchy where overlapping medical conditions are to be resolved by reference to the Statements applicable to each condition, as updated. The cross‑reference mechanism therefore requires claimants and decision‑makers to identify and apply any relevant overlapping Statements.

The Schedule definitions also make cross‑statutory references. The instrument uses the terms MRCA and VEA and points to the corresponding Acts through those abbreviations (Schedule, definitions). The Statement draws on the ICD‑10‑AM coding system for classification (s7(3)‑(4)); it notes that although the ICD code D45 corresponds to polycythaemia vera, the operative meaning for the Statement is the textual definition in s7(2). That counsel prevents mechanical reliance on a coding entry without attending to the instrument’s substantive definition.

The Statement repeals the earlier polycythaemia vera Statement No. 12 of 2013 (s4). The repeal means that subsequent determinations and adjudications within the VEA/MRCA framework will use the current Statement instead of the 2013 version. The instrument provides no transitional provisions; therefore, interactional questions about legacy claims and reliance on the prior Statement would be governed by the VEA/MRCA administrative rules and any applicable common law principles concerning retrospective application and administrative reliance, none of which are set out in this instrument.

Finally, because the instrument sets medical criteria rather than administrative procedures, its primary legal interaction is with the evidentiary and causation doctrines applied by decision‑makers under the VEA and MRCA. The Statement alters the substantive yardstick for causation in polycythaemia vera cases within those regimes; it does not, by itself, alter other legal obligations, nor does it create separate statutory offences or obligations outside the VEA and MRCA framework.

This instrument replaces the earlier Statement of Principles concerning polycythaemia vera No. 12 of 2013. Section 4 expressly repeals that 2013 Statement (s4). The instrument itself is dated 20 August 2021 and its commencement date is 20 September 2021 (s2 and the heading material). The Repatriation Medical Authority affixed its Common Seal to the instrument and the Chairperson’s name appears on the instrument (prefatory material). The authority under which the instrument is made is subsection 196B(3) of the VEA (s3).

No other amendments or historical versions are recorded in the text provided. The instrument’s own Schedule contains definitions that carry forward or refine earlier definitions, such as the definition and method of calculation for "one pack‑year". The instrument’s s11 contemplates that other Statements of Principles made under subsection 196B(3) of the VEA may be amended from time to time and that those amended Statements will apply as in force (s11). That clause builds in dynamic interaction with other Statements as they are amended.

Because the instrument repeals the prior Statement (s4) and becomes the operative Statement from its commencement date (s2), any change to the medical criteria for polycythaemia vera claims that existed under the 2013 Statement will now be governed by the 2021 Statement. The instrument itself contains no schedules of transitional arrangements, savings, or retrospective application clauses in the text provided; therefore, the practical effect of the amendment,how existing or pending claims are treated at the point of repeal and commencement,will be determined by the governing provisions of the VEA and MRCA and administrative practice, which are not set out in this instrument.

To summarise the documentary amendment trail visible in this instrument: (1) the Repatriation Medical Authority issued a new Statement dated 20 August 2021; (2) the instrument commences on 20 September 2021 (s2); and (3) it expressly repeals the prior polycythaemia vera Statement No. 12 of 2013 (s4). The Statement also anticipates ongoing amendment of other Statements and provides that cross‑referenced Statements apply as they are in force from time to time (s11).

The text of the Statement contains no case references, judicial determinations, or litigation history. It is a statutory administrative instrument created under subsection 196B(3) of the VEA (s3) and does not purport to summarise or record any litigation involving polycythaemia vera, claims under the VEA or MRCA, or the prior 2013 Statement. There are no citations to cases, no summaries of judicial treatment, and no recorded challenges within the instrument.

Because the instrument is silent on litigation, any litigation history relevant to the application or interpretation of the factors in this Statement would need to be searched for and obtained from external sources such as court records, tribunal decisions, or administrative review outcomes. The Statement does contain legal cross‑references to other Statements of Principles determined under subsection 196B(3) of the VEA (s11), so where a s9 factor refers to an injury or disease covered by another Statement, the relevant litigation history, if any, for that other Statement may be relevant in practice. However, this instrument itself does not supply any litigation‑related material.

Practitioners should therefore treat the instrument as an authoritative administrative standard setting out the medical factors the Repatriation Medical Authority accepts on the balance of probabilities and be aware that the Statement provides no guidance about how courts or tribunals have interpreted equivalent or prior Statements. Where judicial interpretation may be material to the application of terms such as "inability to obtain appropriate clinical management", "clinical onset", or the temporal connections required by s9 and s10, those interpretive issues will need to be addressed by consulting case law and review decisions external to this document.

The Statement appears concise, but there are several noteworthy points where its wording creates evidentiary or interpretive risks for claimants and decision‑makers.

1. Limited enumerated factors. Section 9 identifies only two factors that the Authority accepts as sufficient for causal connection: quantified smoking exposure and inability to obtain appropriate clinical management. There is no residual "other" factor. This means that, absent one of these factors being proved and related to relevant service under s10, the Statement does not itself provide a basis for finding service connection. The instrument thus narrows the path to a finding on balance of probabilities to these specific factual routes (s9).

2. Precision and calculation in the smoking criterion. The smoking pathway requires at least 10 pack‑years before clinical onset, smoking to have started at least five years before clinical onset, and, if smoking ceased, clinical onset to have occurred within 15 years of cessation (s9(1)). The Schedule defines one pack‑year and gives a calculation method and examples (Schedule, definitions). The Schedule also supplies weight conversions for "equivalent amounts" of tobacco and a gram‑to‑cigarette equivalence for pipe tobacco and cigars (Schedule, Note 1 and Note 2). Failure to document the precise smoking history, or miscalculation of pack‑years, may lead to rejection of the smoking factor.

3. Undefined terms raising discretion. The phrase "inability to obtain appropriate clinical management" in s9(2) is not defined. Section 10(2) limits that factor to situations where the disease was suffered or contracted before or during, but did not arise out of, relevant service, and where the inability to obtain appropriate clinical management materially contributed to or aggravated the condition. That creates a twofold interpretive requirement: a determination about what counts as "appropriate clinical management" and an evaluative judgment about material contribution or aggravation. The absence of definition leaves room for administrative discretion and potential dispute.

4. Timing of "clinical onset" is pivotal yet undefined. Several provisions hinge on "clinical onset of polycythaemia vera" (s9(1)). The Statement does not define how "clinical onset" is to be identified for claims where the course may be indolent or where patients can be asymptomatic (s7(2) Note 2). For persons with "masked" disease, or where diagnosis occurs years after initial pathological changes, establishing the date of clinical onset may be contentious.

Compliance in this context means preparing and presenting the evidence and submissions necessary for a decision‑maker under the VEA or MRCA to conclude, on the balance of probabilities, that polycythaemia vera or death from it is related to relevant service by reference to the factors in this Statement. The Statement itself prescribes the substantive elements that must be proved and supplies definitional tools which constrain how certain elements are calculated (s9, s10, Schedule). The steps below set out what the Statement requires and what evidence will be necessary or useful to align with those requirements.

1. Confirm diagnosis within the Statement’s meaning. The operative definition of polycythaemia vera is in s7(2). Clinical documentation should establish that the condition fits that textual definition and is not an excluded form (relative, familial/congenital, or secondary polycythaemia from hypoxaemia or increased erythropoietin) (s7(2)(c)). Although the instrument notes the ICD‑10‑AM code D45 corresponds to polycythaemia vera, the textual definition controls (s7(3)‑(4)).

2. If relying on the smoking factor (s9(1)):

   • Establish the date of clinical onset of polycythaemia vera. The smoking factor’s temporal tests depend on the onset date: (a) smoking must have commenced at least five years before clinical onset, and (b) if smoking ceased before onset, onset must have occurred within 15 years of cessation (s9(1)). As the instrument does not define "clinical onset", contemporaneous medical records, symptom histories and diagnostic notes that can anchor an onset date will be essential.
   • Calculate pack‑years as set out in the Schedule. The Schedule defines "one pack‑year" and provides the calculation methodology and equivalences (Schedule, definitions and Notes). Document daily cigarette consumption, start and stop dates, and any periods of change in consumption. Where other tobacco products were used, apply the Schedule’s equivalent weight conversions (Schedule, Note 1 and Note 2).
   • Demonstrate that cumulative exposure reaches at least 10 pack‑years prior to the clinical onset date (s9(1)).
   • Ensure records show that smoking commenced at least five years before clinical onset (s9(1)(b)).
   • If cessation occurred before clinical onset, ensure documentation shows that the onset was within 15 years of cessation (s9(1) proviso).

3. If relying on the clinical‑management factor (s9(2)):